New to Cure CMD?
This year’s goal is to register the global CMD community.
Take a moment to register on the CMD International Registry (CMDIR), www.cmdir.org
CMDIR in French, German, Spanish and English. Turkish, Danish and Portuguese coming soon.
Cure CMD and S.A.M. Team Up to Move CMD Therapies Forward
2009 Cure CMD grant cycle awarded over $200,000 in CMD science, click here.
2010 Cure CMD grant application deadline, Sept 15th. For more info, click here
Alex rolls Long Branch 1/2 Marathon, New Jersey
Join Alex and the Cure CMD Team on May 2nd for the Long Branch 1/2 Marathon, New Jersey!
Pre- race spaghetti dinner!
For more info, click here
2010 CMD Family and Affected Individual Conference
Come learn, connect and meet the CMD community!
Registration opens on Cure CMD website, April 1st.
Conference August 14th and15th, Childrens Hospital of Philadelphia, with welcome dinner, Friday, August 13th..
Benjamin and Lucas’ story
Our son, Ben, was born after several years of infertility and much yearning for a blessed child. He was born following a grueling labor and an eventual emergency c-section with the most beautiful face and abundance of black hair like his Dad. He appeared to be a completely healthy child according to our pediatricians. Continue reading Benjamin and Lucas’ story
Cure CMD Research News
Mar 4, 2010: PTC 124 (Ataluren) fails to meet primary endpoints in Phase 2B study
Genzyme Corporation announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). The primary endpoint of change in 6-minute walk distance did not reach statistical significance within the 48-week duration of the study. Study results showed that ataluren was well tolerated and no clinical trial patients discontinued treatment due to an adverse event. Additional efficacy analyses are underway in patient subgroups.
More
Feb 4, 2010: 2009 NIH Funding Estimates for Muscular Dystrophy
The FY2009 estimates of funding by research, condition, and disease categories were released on the NIH RePORT site yesterday. Total FY2009 funding for muscular dystrophy was $66M from the regular NIH appropriation and an additional $17M from the ARRA program. Muscular dystrophy funding level was at $56M in FY2008. More…
Feb 3, 2010: CMD Drug Discovery Meeting
The CMD High Throughput Screen meeting at National Chemical Genomics Center (NCGC) provided the opportunity to discuss CMD targets, development and optimization of target specific assays and expanded screening to NCGC. The meeting set the goal to identify 2 CMD target assays and begin high throughput screening using NCGC resources by 2011. More…
Jan 18, 2010: Seeking Qualified Applicant for Muscle Disease Tenure Track Position
The Iowa Center for Muscular Dystrophy Research seeks outstanding candidates for tenure-track positions at any rank. Successful candidates are expected to establish independent laboratories focusing on skeletal muscle biology and disease. More…
Jan 18, 2010: Muscle Disease Postdoctoral Position Available in Paris
A postdoctoral position is available at the INSERM-UPMC-Paris VI U787-Myology Group, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière (Paris), from March 1st 2010.
The candidates must have a Ph.D. and a strong background either in cell biology/muscle physiology or in molecular biology. Previous experience in microscopy and/or epigenetics will be an important asset.
Research News Archive
Current Trials and Studies
Jan 6, 2010: Merosin Deficient (MDC1A) Clinical Study
Dr. Jim Collins at Cincinnati Children’s Hospital Medical Center (CCHMC) will launch a 1 year trial, Jan/2010- Dec/2010, to identify biomarkers in Merosin Deficient CMD (MDC1A). Dr. Collins and Dr. Carsten Bonnemann at the Children’s Hospital of Philadelphia (CHOP) will enroll infants and children, 0-10 years, with Merosin Deficient CMD.
Contact: Shengyong Hu or Paula Morehart (Division of Neurology, Cincinnati Children’s Hospital Medical Center)
Phone: 513-636-3202 or 513-636-7451
Email: shengyong.hu@cchmc.org More…
Dec 29, 2009: BIO-NMD Study: Biomarkers for Collagen VI Myopathies and Duchenne muscular dystrophy
The BIO-NMD consortium, led by the University of Ferrara’s Dra. Alessandra Ferlini will focus current funding on identifying biomarkers in the Collagen VI myopathies and Duchenne muscular dystrophy. The 3 year project is currently funded through Dec 2012. The study will first evaluate muscle tissue biospecimens available through the EuroBioBank, and then move to evaluate blood and urine specimens for disease specific biomarkers. Preliminary biomarkers identified during the first 18 months, will subsequently be validated in prospective patient cohorts as part of the study.
More…
